Transgene SA reported revenue results for the third quarter and nine months ended September 30, 2018. For the quarter, the company reported revenue from collaborative and licensing agreements of EUR 1.0 million as compared to EUR 0.7 million for the same period last year. Operating revenue was EUR 41.0 million as compared to EUR 5.1 million for the same period last year.

Transgene confirms that it expects 2018 cash burn to be around €25 million based on the current development plan. The financial visibility is confirmed until September 2019 and does not take into account the potential monetization of the Tasly Biopharmaceuticals shares ($48 million), which could extend the cash runway.